Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $14,154 - $16,048
295 Added 7.2%
4,395 $238,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $5,817 - $6,942
-120 Reduced 2.84%
4,100 $210,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $10,478 - $11,716
-181 Reduced 4.11%
4,220 $244,000
Q2 2023

Aug 25, 2023

BUY
$63.71 - $70.74 $280,387 - $311,326
4,401 New
4,401 $281,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $19,712 - $22,359
-300 Reduced 5.5%
5,153 $357,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $8,696 - $10,298
-127 Reduced 2.28%
5,453 $392,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $39 - $23,052
300 Added 5.68%
5,580 $400,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $7,625 - $8,397
-105 Reduced 1.95%
5,280 $405,000
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $331,069 - $396,982
5,385 New
5,385 $393,000
Q2 2021

Aug 13, 2021

SELL
$61.91 - $67.42 $351,215 - $382,473
-5,673 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $157,251 - $176,861
-2,650 Reduced 31.84%
5,673 $358,000
Q4 2020

Jan 13, 2021

SELL
$57.74 - $65.43 $635 - $719
-11 Reduced 0.13%
8,323 $516,000
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $478,621 - $530,375
8,334 New
8,334 $502,000
Q1 2020

May 12, 2020

SELL
$46.4 - $67.43 $236,593 - $343,825
-5,099 Closed
0 $0
Q4 2019

Feb 05, 2020

SELL
$49.21 - $64.19 $23,423 - $30,554
-476 Reduced 8.54%
5,099 $327,000
Q3 2019

Nov 04, 2019

BUY
$42.77 - $50.71 $238,442 - $282,708
5,575 New
5,575 $283,000
Q2 2019

Jul 29, 2019

SELL
$44.62 - $49.34 $191,598 - $211,865
-4,294 Closed
0 $0
Q1 2019

Apr 11, 2019

BUY
$45.12 - $53.8 $83,562 - $99,637
1,852 Added 75.84%
4,294 $205,000
Q4 2018

Jan 22, 2019

BUY
$48.76 - $63.23 $119,071 - $154,407
2,442 New
2,442 $127,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Lavaca Capital LLC Portfolio

Follow Lavaca Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lavaca Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lavaca Capital LLC with notifications on news.